Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 18:8:752468.
doi: 10.3389/fcvm.2021.752468. eCollection 2021.

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease

Chung-Ming Fu  1 , Lung-Chih Li  1   2 , Yueh-Ting Lee  1 , Shih-Wei Wang  3 , Chien-Ning Hsu  3   4
Affiliations

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease

Chung-Ming Fu et al. Front Cardiovasc Med. .

Abstract

Background and Objectives: Real-world evidence of apixaban treatment in patients with chronic kidney disease remains scarce. This study aimed to compare the relative risk of stroke or systemic embolism (SE) and major bleeding between apixaban and warfarin in atrial fibrillation (AF) patients with different degrees of kidney function. Design, Setting, Participants, and Measurements: We evaluated newly diagnosed AF patients between 2004 and 2018, who were receiving apixaban or warfarin. Electronic medical record data were collected from a large healthcare delivery network in Taiwan. The outcomes of hospitalization for stroke/SE and major bleeding were compared with propensity-score matched apixaban and warfarin cohorts. Stratified analyses according to initial apixaban dose (standard dose of 10 mg/day vs. lower dose of 2.5-5.0 mg/day) and baseline estimated glomerular filtration rate were performed. Results: Each cohort involved 1,625 matched patients. Apixaban was significantly associated with a lower risk of stroke/SE (adjusted hazard ratio [aHR]: 0.74; 95% confidence interval [CI]:0.57-0.97; p = 0.03). The risk of major bleeding was not increased whether in standard doses (aHR: 0.66; 95% CI: 0.45-0.96; p = 0.03) or reduced doses (aHR, 0.84; 95% CI, 0.63-1.12; p = 0.23) of apixaban. Regarding kidney function, apixaban reduced the risk of stroke/SE by 37% in those with an eGFR of <30 ml/min/1.73 m2 (aHR: 0.63; 95% CI: 0.40-0.98; p = 0.04). Conclusions: Compared to warfarin, apixaban is associated with a reduced risk of stroke/SE and is consistent with a subset of AF patients with eGFR <30 ml/min/1.73 m2. Both standard and reduced doses of apixaban showed lower risk of major bleeding than those of warfarin.

Keywords: apixaban; atrial fibrillation (AF); bleeding; chronic kidney disease; ischemic stroke; thromboembolism; warfarin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Patient inclusion flowchart.
Figure 2
Figure 2
Cumulative incidences of (A) ischemic stroke/systemic embolism in the matched cohort, (B) ischemic stroke/systemic embolism in the subgroup of patients with advanced CKD (eGFR <30 ml/min/1.73 m2), (C) major bleeding in the matched cohort, and (D) major bleeding in the subgroup of patients with eGFR <30 ml/min/1.73 m2.
Figure 3
Figure 3
Stratified analyses for the risk of (A) ischemic stroke/systemic embolism and (B) major bleeding in the apixaban-warfarin matched cohort. aHR: adjusted hazard ratio; 95% CI, 95% confidence interval; eGFR: estimated glomerular filtration rate (ml/min/1.73 m2).
See this image and copyright information in PMC

References

    1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. . Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. (2019) 139:e56–e528. 10.1161/CIR.0000000000000659 - DOI - PubMed
    1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. (2009) 361:1139–51. 10.1056/NEJMoa0905561 - DOI - PubMed
    1. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. (2013) 369:2093–104. 10.1056/NEJMoa1310907 - DOI - PubMed
    1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. (2011) 365:981–92. 10.1056/NEJMoa1107039 - DOI - PubMed
    1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. (2011) 365:883–91. 10.1056/NEJMoa1009638 - DOI - PubMed